Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans

US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.